RxDoctor Payments Data

Jason Swanner, MD

Ophthalmology · Hoover, ALNPI 1679593719

Payments from drug & device makers

$1,686in general payments, 2019–2025

Across 42 payments — averaging $40.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$796
  • AbbVie$426
  • Glaukos Corporation$283
  • NEW World Medical,inc.$136
  • Thea Pharma Inc.$23
  • Johnson & Johnson Surgical Vision, Inc.$22

What the payments were for

  • Travel & lodging$29818%
  • Food & beverage$1,38882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686 in reported general payments places this provider in the 45th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$330,601
Medicare patients
860
Services billed
2,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost367$124,121
RestasisCyclosporine46$56,573
Prednisolone Acetate739$48,277
Latanoprost2,459$42,625
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,147$26,957
CombiganBrimonidine Tartrate/Timolol66$24,154
Brimonidine Tartrate469$20,141
Travoprost108$18,339
Cyclosporine27$18,280
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol68$17,073
Ketorolac Tromethamine610$11,579
Dorzolamide Hcl529$11,513
Timolol Maleate708$11,030
Timolol MaleateTimolol Maleate/Pf20$8,349
Ofloxacin664$8,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$426$204,847479 claims
AlconSimbrinza$796$2,42312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Hoover

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →